2/16/2018 1
Confirming the diagnosis of epilepsy at first presentation
Jacqueline A French MD Professor of Neurology NYU Langone School of Medicine
- I am President of the Epilepsy Study Consortium. All consulting is done on behalf of the
consortium, and fees are paid to the consortium. The NYU Comprehensive Epilepsy Center receives salary support from the consortium;
- I have acted as a consultant for Acadia, Acorda, Adamas, Alexza, Anavex, Axcella
Health, Biogen, BioPharm Solutions, Cavion, Cerecor, Concert Pharmaceuticals, Covance, CuroNZ, Eisai, Empatica, Engage, Georgia Regents University, Glaxo Smith- Kline, GW Pharma, J&J Pharmaceuticals, Marinus, MonosolRx, Monteris, Nestle-Health Science, Neurelis, Novartis, Otsuka, Ovid, Pfizer, Pfizer-Neusentis, Sage Therapeutics, Shire, SK Life Sciences, Sunovion, Takeda, UCB Inc., Upsher Smith, Ultragenyx, Xenon Pharmaceuticals, Xeris, Zogenix and Zynerba
- I have received grants from Acorda, Alexza, Eisai Medical Research, LCGH, Lundbeck,
Pfizer, SK Life Sciences, Sunovion, Takeda, and UCB, Epilepsy Research Foundation, Epilepsy Study Consortium, Epilepsy Therapy Project, and NINDS
- I am on the editorial board of Lancet Neurology, Neurology Today and Epileptic
disorders.
Disclosures
- Two major recent events in first epilepsy
diagnosis
- ILAE new definition of epilepsy
- AAN guideline on treatment of a single
seizure
Newly diagnosed epilepsy
- The new ILAE “practical” definition of epilepsy is:
- At least two unprovoked (or reflex) seizures occurring >24
h apart;
- One unprovoked (or reflex) seizure and a probability of
further seizures similar to the general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 10 years;
- Diagnosis of an epilepsy syndrome.
New diagnosis of Epilepsy
Fisher R et al. LAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014 Apr;55(4):475-82